AstraZeneca price target raised to $219 from $109 at Morgan Stanley

Morgan Stanley raised the firm’s price target on AstraZeneca (AZN) to $219 from $109 and keeps an Overweight rating on the shares. The firm said its risk/reward for AstraZeneca has been updated. AstraZeneca continues to offer sector leading earnings growth, with the firm’s more optimistic view on the pipeline driving longer-term earnings ahead of the Street, the analyst tells investors in a research note. While the 1H26 catalyst path creates a trickier setup, the risk/reward appears more attractive from 2H26, the analyst adds.